Work Here?
About Arcellx
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2014
Overview
Arcellx develops immunotherapies aimed at transforming cell therapy for serious diseases. The company focuses on creating proprietary products that utilize advanced cell therapy techniques. Their approach involves extensive research and development to ensure the safety and effectiveness of their treatments. Arcellx differentiates itself from competitors by concentrating on unmet medical needs and forming partnerships and licensing agreements to support their commercialization efforts. The ultimate goal of Arcellx is to provide innovative treatment options for patients through successful regulatory approval and product sales.
Simplify's Take
What believers are saying
- Partnership with Kite enhances Arcellx's multiple myeloma program development.
- Recent clinical data shows robust long-term responses for anito-cel.
- Advancements in gene editing could improve Arcellx's CAR-T product efficacy.
What critics are saying
- Competition from Legend Biotech and Johnson & Johnson's Carvykti is significant.
- High R&D costs pose financial risks for Arcellx.
- Regulatory changes could impact cell therapy approval processes.
What makes Arcellx unique
- Arcellx's CART-ddBCMA has Fast Track, Orphan Drug, and RMAT designations.
- The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
- Anito-cel uses a novel D-Domain BCMA binder for enhanced antigen binding.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$628.8M
Above
Industry Average
Funded Over
4 Rounds
New Enterprise AssociatesBenefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↑ 2%Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible
REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody
REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody
Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.
Arcellx is Hiring for 33 Jobs on Simplify!
Find jobs on Simplify and start your career today
Training
1 Open Roles
People Also Viewed
Discover companies similar to Arcellx
About Arcellx
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2014
Arcellx is Hiring for 33 Jobs on Simplify!
Find jobs on Simplify and start your career today
Training
1 Open Roles
People Also Viewed
Discover companies similar to Arcellx